AMP-303
AMP-303 is in Phase 1 for androgenetic alopecia, developed by Amplifica.
An intradermal injection that its sponsor reports produced a hair-count increase over placebo in an unregistered first human trial, and is not the SCUBE3 programme it gets confused with.
- Developed by
- Amplifica
- Current phase
- Phase 1
- Mechanism
- Other
- Indications
- Androgenetic alopecia
- Also known as
- AMP303
- Last public activity
- No trials on record
- Copy last reviewed
- September 2026
- Record confidence
- Medium
First tests in humans. Answers 'is it safe?', not 'does it work?'.
A mechanism that doesn't fit the categories above.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
How it is meant to work
Amplifica describes AMP-303 as a novel polysaccharide and has not published its target. It is worth separating from SCUBE3, the molecule licensed from UC Irvine that the company develops separately as AMP-506; the two are easily conflated.
Why it matters
The first-in-human trial used a split-scalp design, injecting one side and placebo the other, which controls for the thing hair-loss trials control worst. The sponsor reports a statistically significant proportion of subjects with a greater than 15% increase in non-vellus hair count over placebo at 60 days, still above 10% at 150 days, from a single treatment cycle; the results were presented as a poster in 2025. Read it as an early safety-and-signal study rather than an efficacy result: the trial is not registered, enrolment has not been disclosed, and the data are sponsor-reported.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
No trials matched to this programme in ClinicalTrials.gov.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Amplifica's AMP-303 Study Unveils New Hope for Hair Loss Treatments — Company release
- Androgenetic alopecia treatment funding: Amplifica's AMP-303 and the SCUBE3-based AMP-506 — Press, August 2026
- Amplifica to present positive clinical outcomes for AMP-303, a novel polysaccharide, at the Society for Investigative Dermatology annual meeting — Company release, May 2025
Related programmes
Other programmes in the register with the same approach.
Cite this page
Hair Pipeline, "AMP-303 — development record", hairpipeline.com/pipeline/amp-303